Poly-L-lactic acid is a biodegradable synthetic polymer used in selected injectable medical products. In aesthetic practice it is commonly discussed as a biostimulatory material because its clinical effect develops progressively through a controlled tissue response rather than through permanent placement of an immediately volumising gel. The early appearance produced by reconstitution fluid should not be confused with the later treatment outcome.
This programme develops the clinical reasoning required to use PLLA responsibly. Participants learn to connect facial assessment, tissue quality, volume distribution, anatomy and patient objectives with a conservative, staged treatment plan. The course also examines where PLLA may be unsuitable, where another modality may be more appropriate and why excessive treatment or incorrect placement can create delayed problems.
The course is deliberately product-neutral at programme level. It teaches transferable principles while making clear that PLLA products are not automatically interchangeable. Every clinical step—from reconstitution and storage to treatment areas, plane, administration technique and aftercare—must be checked against the current instructions for the actual product used.
Theory is supported by demonstration and an edition-specific practical component. Completion provides structured education but does not independently establish clinical competence, extend professional scope or guarantee authorisation to practise.
Verified healthcare qualification and current professional registration where applicable
Lawful professional scope for injectable aesthetic procedures
Appropriate professional indemnity or confirmed training cover
Previous training and experience in facial anatomy and injectable practice
Ability to recognise and initiate emergency management of injectable complications
Completion of required pre-course learning and product documentation
Compliance with model, consent, dress and equipment requirements for the edition
PLLA material science, biodegradation and tissue response
Clear distinction between PLLA biostimulation and immediate volumising fillers
Facial ageing, fat compartments, structural support and skin-quality assessment
Consultation, patient selection, expectations and informed consent
Contraindications, precautions and reasons to defer or decline treatment
Product verification, regulatory status, IFU and batch traceability
Product-specific reconstitution, hydration, storage and handling
Relevant vascular, neural and layered facial anatomy
Conservative full-face planning without universal maps or fixed vial counts
Needle and cannula considerations within the selected product IFU
Asepsis, documentation, photography and procedural workflow
Prevention of papules, nodules, granulomas, infection and contour irregularity
Recognition and emergency escalation of vascular or visual symptoms
Aftercare, review, staged decision-making and longitudinal treatment planning
Supervised practical learning in the confirmed edition format
• Polymer characteristics, particles, biodegradation and tissue response
• Progressive effect and the limits of the term “collagen stimulator”
• PLLA compared with hyaluronic acid, calcium hydroxylapatite and other modalities
• Evidence literacy: product-specific studies versus class-wide assumptions
• Concerns, goals, expectations and alternatives
• Medical and aesthetic history, medications and previous procedures
• Contraindications, precautions and referral thresholds
• Consent for gradual, variable and potentially delayed outcomes
• Skeletal framework, fat compartments, tissue descent and skin quality
• Symmetry, facial proportions and baseline photography
• Choosing treatment priorities rather than chasing individual lines
• Staged planning, review and avoiding early overcorrection
• Relevant facial layers, vessels, nerves and retaining structures
• High-risk territories and danger signs
• Entry-point, plane and instrument considerations
• Why aspiration or cannula use cannot eliminate vascular risk
• CE status/intended purpose or applicable local authorisation
• IFU, packaging integrity, expiry, lot recording and storage
• Product-specific reconstitution, hydration, agitation and permitted additives
• Aseptic non-touch technique and time limits for use
• Treatment-room preparation and emergency readiness
• Marking, positioning, cleansing and documentation
• Conservative administration using the confirmed product and technique
• Demonstration, simulation and supervised hands-on practice as applicable
• Immediate observations and expected short-term responses
• Product-specific aftercare and massage instructions where applicable
• Review timing, photography and decision to observe, repeat, modify or stop
• Sequencing with fillers, toxins, energy devices and other procedures
• Papules, nodules, granulomatous reactions and delayed inflammation
• Infection, biofilm concerns, asymmetry and contour irregularity
• Vascular compromise and urgent visual/neurological symptoms
• Documentation, disclosure, referral and follow-up responsibility
• Why PLLA cannot be managed as if it were hyaluronic acid
Training begins with the biology and material science of PLLA. Participants examine how particle-based injectable products differ from hyaluronic-acid gels, why visible change is progressive, why early overcorrection is unsafe and why the evidence for one product cannot automatically be applied to every PLLA formulation.
The consultation module uses a structured assessment of facial proportions, skeletal support, fat compartments, skin quality, asymmetry, previous treatments and the patient’s priorities. Rather than treating age or a single line, participants learn to define a realistic clinical objective, identify limitations and consider alternatives or combination approaches without creating an automatic multi-modality plan.
Anatomy is taught as a decision-making framework. Relevant tissue layers, vessels, nerves, retaining structures and high-risk territories are linked to entry-point, plane and instrument selection. There is no universal injection map. Treatment design must reflect the individual face, the selected product’s intended use and the practitioner’s verified competence.
Product handling follows the actual IFU. Participants review product identity, packaging integrity, expiry, batch recording, reconstitution materials, aseptic preparation, hydration or standing requirements, storage, permitted additives and time limits for use. They learn why protocols borrowed from another brand can compromise safety and performance.
The procedural module follows the clinical journey from consent, photography and marking to preparation, conservative administration, endpoint awareness, documentation and aftercare. The practical format may combine demonstration, simulation, treatment planning and supervised model work, but live treatment occurs only when all clinical-governance conditions are met.
Complication prevention and response are integrated throughout. The programme distinguishes expected short-term reactions from warning signs and delayed events. Particular attention is given to product misplacement, papules, nodules, inflammatory or granulomatous reactions, infection, contour irregularity, vascular compromise and visual or neurological symptoms requiring emergency escalation.
This programme is intended for appropriately qualified healthcare professionals who already have a sound foundation in facial anatomy, consultation, infection prevention and injectable practice, and whose professional registration, lawful scope and indemnity permit them to undertake or progress toward PLLA procedures.
It is not designed as a first introduction to needles, facial anatomy or medical-aesthetic consultation. Final eligibility is confirmed for each edition and may depend on profession, registration, experience and the practical format.
